Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lotus Pharmaceutical Co., Ltd. (1795.TW)
Taipei, TW
Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and other global territories. The company primarily targets therapeutic areas such as oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system conditions with its generic product line. In addition to prescription generics, Lotus also offers a diverse array of over-the-counter drugs. Diversifying its business activities, the firm engages in the wholesale distribution of cosmetics, the retail of specialized clinical equipment, and provides biotechnology consulting. It also handles the sale of pharmaceuticals and medicinal chemicals, conducts marketing campaigns, offers market planning and business intelligence services, and provides advisory on health management and health technology. Furthermore, Lotus delivers a suite of services including project management for pharmaceutical regulatory compliance, data collection, and agency functions. It also operates as a healthcare consultancy and a Contract Research Organization (CRO). Established in 1966, Lotus Pharmaceutical Co., Ltd. maintains its principal office in Taipei City, Taiwan. The company is a subsidiary of Alvogen Emerging Markets Holdings Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.85% | -3.02% | -14.82% | -32.81% | -32.34% | -31.98% | -14.82% | -42.02% | +123.84% | +205.56% | +973.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | -1 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.4% ★ Q1'26: +82.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-6.3% Q1'26: -60.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+28.1% ★ Q1'26: -2.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+28.8% ★ Q1'26: +22.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.8% ★ Q1'26: +8.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.7% ★ Q1'26: -0.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×7.52× Q1'26: 5.46× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.52B
est: 4.15B (+33.1%)
|
5.90B
est: 3.09B (+91.0%)
|
6.42B
est: 6.34B (+1.4%)
|
6.43B
est: 6.35B (+1.2%)
|
9.17B
est: 9.07B (+1.1%)
|
10.73B
est: 10.64B (+0.8%)
|
12.65B
est: 12.65B (+0.0%)
|
14.63B
est: 14.40B (+1.6%)
|
16.96B
est: 16.93B (+0.1%)
|
18.58B
est: 18.50B (+0.5%)
|
20.51B
est: 19.93B (+2.9%)
|
34.26B
30.57B – 37.28B
+71.9% YoY
|
37.65B
33.12B – 42.18B
+9.9% YoY
|
| EBITDA |
960.37M
est: 1.37B (-30.1%)
|
592.08M
est: 1.02B (-42.2%)
|
856.08M
est: 2.10B (-59.2%)
|
874.97M
est: 2.10B (-58.4%)
|
1.92B
est: 3.01B (-36.1%)
|
2.34B
est: 3.53B (-33.5%)
|
2.93B
est: 4.19B (-30.2%)
|
5.26B
est: 4.77B (+10.2%)
|
6.87B
est: 8.58B (-19.9%)
|
8.21B
est: 9.38B (-12.4%)
|
7.44B
est: 10.10B (-26.4%)
|
17.37B
15.49B – 18.90B
+71.9% YoY
|
19.08B
16.79B – 21.38B
+9.9% YoY
|
| EBIT |
448.84M
est: 1.10B (-59.2%)
|
297.25M
est: 819.37M (-63.7%)
|
495.32M
est: 1.68B (-70.5%)
|
483.71M
est: 1.68B (-71.3%)
|
1.33B
est: 2.41B (-44.8%)
|
1.63B
est: 2.82B (-42.1%)
|
2.17B
est: 3.35B (-35.4%)
|
4.32B
est: 3.82B (+13.2%)
|
5.66B
est: 7.16B (-20.9%)
|
6.93B
est: 7.82B (-11.3%)
|
5.90B
est: 8.43B (-29.9%)
|
14.48B
12.92B – 15.76B
+71.9% YoY
|
15.91B
14.00B – 17.83B
+9.9% YoY
|
| Net Income |
103.95M
est: 477.85M (-78.2%)
|
-134.04M
est: 2.97B (-104.5%)
|
7.69M
est: 138.28M (-94.4%)
|
99.48M
est: 209.91M (-52.6%)
|
662.81M
est: 952.19M (-30.4%)
|
1.03B
est: 1.06B (-3.4%)
|
1.40B
est: 1.45B (-3.0%)
|
3.02B
est: 2.87B (+5.2%)
|
4.11B
est: 4.01B (+2.3%)
|
5.07B
est: 4.86B (+4.2%)
|
4.72B
est: 4.95B (-4.7%)
|
4.14B
4.06B – 4.87B
-16.3% YoY
|
6.10B
6.07B – 6.29B
+47.1% YoY
|
| SGA |
2.48B
est: 918.72M (+170.1%)
|
2.63B
est: 684.32M (+284.5%)
|
2.23B
est: 1.40B (+58.7%)
|
2.37B
est: 1.41B (+68.2%)
|
2.58B
est: 2.01B (+28.4%)
|
2.48B
est: 2.36B (+5.2%)
|
2.71B
est: 2.80B (-3.1%)
|
3.18B
est: 3.19B (-0.4%)
|
3.76B
est: 3.80B (-0.9%)
|
4.13B
est: 4.15B (-0.3%)
|
5.02B
est: 4.47B (+12.4%)
|
7.68B
6.85B – 8.36B
+71.9% YoY
|
8.44B
7.43B – 9.46B
+9.9% YoY
|
| EPS |
0.44
est: 1.81 (-75.7%)
|
-0.56
est: 11.27 (-105.0%)
|
0.09
est: 0.53 (-82.9%)
|
0.42
est: 0.80 (-47.3%)
|
3.11
est: 3.62 (-14.0%)
|
4.23
est: 4.04 (+4.8%)
|
5.50
est: 5.49 (+0.1%)
|
11.59
est: 12.07 (-4.0%)
|
15.72
est: 15.35 (+2.4%)
|
19.35
est: 18.41 (+5.1%)
|
18.14
est: 19.05 (-4.8%)
|
17.02
15.54 – 18.60
-10.6% YoY
|
23.62
23.18 – 24.05
+38.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.09% | 63.3K | 0.74% |
| 2 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.08% | 96.9K | 0.42% |
| 3 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.07% | 511.1K | 0.65% |
| 4 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.07% | 249.1K | 0.72% |
| 5 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.06% | 348.2K | 0.55% |
| 6 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.06% | 193.7K | 0.74% |
| 7 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.05% | 925.1K | 0.58% |
| 8 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.03% | 142.0K | 0.33% |
| 9 | Avantis Emerging Markets Value ETF AVES | 0.03% | 438.8K | 0.36% |
| 10 | WisdomTree Emerging Markets SmallCap Dividend UCITS ETF DGSD.L | 0.03% | 11.6K | 0.54% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Petar Antonov Vazharov | Chief Executive Officer & Director | 53M | male |
| Bjartur Shen | Vice President of Strategies & Finance | 29M | male |
| Manish Chawla | Vice President of Research and Development | 14M | male |
| Gwen Hsieh | Chief Information Officer | 9M | female |
| Eeling Chan | Chief Financial Officer | 5M | female |
| Yi Ling Tian | Accounting Supervisor | — | — |
| Edin Buljubasic | Vice President of Legal and Compliance | — | male |
| Fiona Lei | Head of Human Resources | — | female |
| Jeffrey Tsang | Head of Investor Relations & Corporate Communications | — | male |
| Vamsi Kiran Kosaraju | Chief Operations Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1795.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
